Early success for Biosignal's anti-bacterial contact lenses
Monday, 20 September, 2004
Biosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones.
The 24 hour trial showed 85 per cent efficacy against Pseudomonas aeruginosa and up to 100 per cent efficacy against Staphylococcus aureus.
"This outcome is extremely attractive to the competitive contact lens market, which has a preference for a permanently attached active. This method is more likely to provide longer life anti-bacterial efficacy with a shortened product registration process," said managing director and CEO Mr Michael Oredsson, in a statement.
IER and Biosignal are currently testing a range of furanones and attachment strategies in vitro and expect to enter their first small human trial in the first half of 2005.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
